Comment

Unified understanding of MS course is required for drug development

The treatment of multiple sclerosis (MS) has evolved remarkably over the past 25 years. This progress has been enabled by advances in research, drug development and active engagement of the scientific community with regulatory authorities. However, an inconsistent approach to MS disease courses could have a negative impact on the drug development process.

  • Subscribe to Nature Reviews Neurology for full access:

    $199

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    [No authors listed.] FDA approves new drug to treat multiple sclerosis. US Food and Drug Administration (2017).

  2. 2.

    [No authors listed.] New medicine for multiple sclerosis. European Medicines Agency (2017).

  3. 3.

    et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278–286 (2014).

  4. 4.

    Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis (European Medicines Agency, 2015).

  5. 5.

    U.S. Food and Drug Administration. Ocrelizumab Summary Review. US Food and Drug Administration (2017).

Download references

Acknowledgements

A.J.T. acknowledges support from the UCL/UCLH National Institute of Health (NIHR) Biomedical Research Centre (BRC).

Author information

Affiliations

  1. National Multiple Sclerosis Society, 733 Third Avenue, New York, New York 10017, USA.

    • Timothy Coetzee
  2. Faculty of Brain Sciences, University College London, 149 Tottenham Court Road, London W1T 7NF, UK.

    • Alan J. Thompson

Authors

  1. Search for Timothy Coetzee in:

  2. Search for Alan J. Thompson in:

Competing interests

A.J.T. is chair and T.C. a member of the International Progressive MS Alliance Scientific Steering Committee.

Corresponding author

Correspondence to Alan J. Thompson.